jazotartib

Jazotartib is an investigational drug that has been studied for its potential as a treatment for certain types of cancer. It is a small molecule inhibitor, meaning it is designed to block the activity of specific proteins within cancer cells that are crucial for their growth and survival. Specifically, jazotartib targets enzymes involved in DNA repair pathways. By inhibiting these enzymes, jazotartib aims to make cancer cells more vulnerable to DNA damage and ultimately lead to their death.

Clinical trials have explored the use of jazotartib in various solid tumors and hematological malignancies. Early research has focused on its safety profile and efficacy, often in combination with other standard cancer therapies. The development of jazotartib is part of a broader effort to develop targeted therapies that offer more precise treatment options with potentially fewer side effects compared to traditional chemotherapy. Further research and clinical trials are ongoing to determine its full potential and optimal use in cancer treatment. The drug is not yet approved by major regulatory agencies for widespread clinical use.